R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 58.41 CNY -2.81% Market Closed
Market Cap: 5.6B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

R&G PharmaStudies Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Cash from Operating Activities
ÂĄ192.6m
CAGR 3-Years
63%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cash from Operating Activities
ÂĄ12.8B
CAGR 3-Years
40%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash from Operating Activities
ÂĄ2.6B
CAGR 3-Years
11%
CAGR 5-Years
24%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash from Operating Activities
ÂĄ3.2B
CAGR 3-Years
13%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash from Operating Activities
ÂĄ1.1B
CAGR 3-Years
-4%
CAGR 5-Years
15%
CAGR 10-Years
37%
W
WuXi XDC Cayman Inc
HKEX:2268
Cash from Operating Activities
ÂĄ332.8m
CAGR 3-Years
262%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5.6B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
57.24 CNY
Overvaluation 2%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
192.6m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Cash from Operating Activities amounts to 192.6m CNY.

What is R&G PharmaStudies Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
63%

Over the last year, the Cash from Operating Activities growth was 48%. The average annual Cash from Operating Activities growth rates for R&G PharmaStudies Co Ltd have been 63% over the past three years .

Back to Top